MS Patients Choose Death Risk With Biogen Idec, Inc. (Massachusetts) (BIIB)'s Potent Drug Treatment  
5/23/2013 8:26:23 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Kari Antin, a 40-year-old financial analyst in Minneapolis, knows she’s taking a life-or-death risk with every monthly infusion of Biogen (BIIB) Idec Inc.’s Tysabri. She is among the 55 percent of multiple sclerosis patients who harbor a potentially lethal virus that can be reactivated by the drug, allowing it to creep from the kidneys to the brain, where it destroys cells that protect the nerves. The risk soars after two years of treatment. Still, Antin insists on sticking with the drug she credits with restoring her health.

Hey, check out all the research scientist jobs. Post your resume today!